IMRX — Immuneering Corp
NASDAQ · Healthcare · Biotechnology
$4.85
+$0.00 (+0.00%)
Immuneering Corp (IMRX) is a biotechnology company listed on NASDAQ. It is led by Benjamin J. Zeskind M.B.A., Ph.D., based in 245 Main Street, Cambridge, MA, United States, 02142, with about 54 employees. Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Net income was -$15.0M. IMRX currently screens at market cap $124.2M.
Use this IMRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Immuneering Corp even when a live quote feed is slow.
About Immuneering Corp
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
IMRX Key Statistics
Market Cap
$124.15M
Volume
7,518
Previous Close
$5.18
Day Range
$5.20 – $5.31
EPS
-$2.04
Revenue
$0.00
Net Income
-$61.04M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
54
IMRX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $316.95K | $2.08M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$61.04M | -$53.47M | -$50.51M | -$33.54M |
| EPS (Diluted) | -$2.04 | -$1.88 | -$1.91 | -$2.46 |
Total Assets
$52.71M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$36.14M
Operating Cash Flow
-$55.00M
Free Cash Flow
$0.00
Immuneering Corp Company Information
- Co-Founder, President, CEO & Director
- Benjamin J. Zeskind M.B.A., Ph.D.
- Headquarters
- 245 Main Street, Cambridge, MA, United States, 02142
- Website
- immuneering.com
- Phone
- 617 500 8080
- IPO / Founded
- 2021-07-30
- Sector
- Healthcare
- Industry
- Biotechnology